Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 62

Sort by

Sort Order Select

Journal Articles

Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma

Blood (2020) 136 (Supplement 1): 10–12.

https://doi.org/10.1182/blood-2020-136550

Published: 2020

Journal Articles

Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL)

Shulan Tian, MS, PhD, Hanyin Wang, MD, Timothy G. Call, MD, Eric W. Klee, PhD, Minetta C. Liu, MD, Erik Jessen, PhD, Sameer A. Parikh, MD, Yucai Wang, MDPhD, Saad S. Kenderian, MB, ChB, Jose F. Leis, MD PhD, Min Shi, MDPhD, Eli Muchtar, MD, Daniel L. Van Dyke, PhD, Amber B. Koehler, PA-C, MS, Neil E. Kay, MD, Susan L. Slager, PhD, Esteban Braggio, PhD, Huihuang Yan, PhD, Wei Ding, MD PhD

Blood (2020) 136 (Supplement 1): 16–17.

https://doi.org/10.1182/blood-2020-138397

Published: 2020

Journal Articles

Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

John N. Allan, MD, Tait Shanafelt, MD, Adrian Wiestner, MD PhD, Carol Moreno, MD PhD, Susan M. O'Brien, MD, Esteban Braggio, PhD, Emily Liu, MS, James P. Dean, MD PhD, Dominic Lai, PharmD, Inhye E. Ahn, MD

Blood (2020) 136 (Supplement 1): 23–24.

https://doi.org/10.1182/blood-2020-134431

Published: 2020

Journal Articles

Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes

Geffen Kleinstern, PhD, J. Brice Weinberg, MD, Sameer A. Parikh, MD, Esteban Braggio, PhD, Dennis P. Robinson, Aaron D. Norman, MPH, Kari G Rabe, Celine M. Vachon, PhD, Connie E. Lesnick, Timothy G. Call, MD, Danielle M. Brander, MD, Janet E. Olson, PhD, James R. Cerhan, MD PhD, Neil E. Kay, MD, Curtis A. Hanson, MD, Richard R. Furman, MD, Tait Shanafelt, MD, Susan L. Slager, PhD

Blood (2020) 136 (Supplement 1): 35–36.

https://doi.org/10.1182/blood-2020-136548

Published: 2020

Journal Articles

Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older

Paul J. Hampel, MD, Timothy G. Call, MD, Kari G Rabe, Sara J. Achenbach, Eli Muchtar, MD, Saad S. Kenderian, MB, ChB, Yucai Wang, MDPhD, Amber B. Koehler, PA-C, MS, Jose F. Leis, MD PhD, Susan M. Schwager, Daniel L. Van Dyke, PhD, Min Shi, MDPhD, Curtis A. Hanson, MD, Tait Shanafelt, MD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Wei Ding, MD PhD, Sameer A. Parikh, MD

Blood (2020) 136 (Supplement 1): 26–27.

https://doi.org/10.1182/blood-2020-137578

Published: 2020

Journal Articles

Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia

Blood (2020) 136 (Supplement 1): 12–13.

https://doi.org/10.1182/blood-2020-139068

Published: 2020

Journal Articles

Measles, Mumps & Rubella Titers Post Autologous Stem Cell Transplant in Multiple Myeloma Patients Induced with Modern Therapy

Mariano Arribas, Gregory J Ahmann, BS, Skye Buckner-Petty, MPH, Esteban Braggio, PhD, Elitza S Theel, PhD, Rafael Fonseca, MD

Blood (2020) 136 (Supplement 1): 43.

https://doi.org/10.1182/blood-2020-142616

Published: 2020

Journal Articles

Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib

Hanyin Wang, MD, Shulan Tian, MS, PhD, Qing Zhao, Wendy Blumenschein, Jennifer H. Yearley, PhD, Charla R. Secreto, Sutapa Sinha, PhD, Timothy G. Call, MD, Yucai Wang, MDPhD, Sameer A. Parikh, MD, Saad S. Kenderian, MB, ChB, Rong He, MD, Jose F. Leis, MD PhD, Min Shi, MDPhD, Neil E. Kay, MD, Susan L. Slager, PhD, Esteban Braggio, PhD, Huihuang Yan, PhD, Wei Ding, MD PhD

Blood (2020) 136 (Supplement 1): 30–31.

https://doi.org/10.1182/blood-2020-136172

Published: 2020

Journal Articles

Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia

Zhiquan Wang, PhD, Justin C. Boysen, Huihuang Yan, PhD, Charla R. Secreto, Sameer A. Parikh, MD, Saad S. Kenderian, MB, ChB, Wei Ding, MD PhD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD

Blood (2020) 136 (Supplement 1): 1.

https://doi.org/10.1182/blood-2020-140309

Published: 2020

Journal Articles

Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)

Geffen Kleinstern, PhD, Daniel R O'Brien, Brian Kabat, B.S., Kari G Rabe, Aaron D. Norman, Huihuang Yan, PhD, Celine M. Vachon, PhD, Shulan Tian, MS, PhD, Timothy G. Call, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, James R. Cerhan, MD PhD, Neil E. Kay, MD, Esteban Braggio, PhD, Susan L. Slager, PhD

Blood (2019) 134 (Supplement_1): 852.

https://doi.org/10.1182/blood-2019-124346

Published: 2019

Journal Articles

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Blood (2019) 134 (Supplement_1): 33.

https://doi.org/10.1182/blood-2019-126824

Published: 2019

Journal Articles

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

Brian Giacopelli, BS, Kari G. Chaffee, MS, Yue-zhong Wu, MSc, John C. Byrd, MD, Tait D. Shanafelt, MD, Sameer A. Parikh, MD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Christopher C. Oakes, PhD

Blood (2019) 134 (Supplement_1): 3022.

https://doi.org/10.1182/blood-2019-123564

Published: 2019

Journal Articles

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Paul J. Hampel, MD, Timothy G. Call, MD, Sara J. Achenbach, Kari G Rabe, Wei Ding, MD PhD, Eli Muchtar, MD, Saad S. Kenderian, MD, Yucai Wang, MD PhD, Amber Koehler, PA-C, MS, Amie Fonder, PA-C, MS, Jose F. Leis, MD PhD, Susan M. Schwager, Daniel L. Van Dyke, PhD, Esteban Braggio, PhD, Susan L. Slager, PhD, Neil E. Kay, MD, Sameer A. Parikh, MD

Blood (2019) 134 (Supplement_1): 3050.

https://doi.org/10.1182/blood-2019-125411

Published: 2019

Journal Articles

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Tiziana Vaisitti, PhD, Katti Jessen, PhD, Thanh-Trang Vo, PhD, Mira Ko, Francesca Arruga, PhD, Nicoletta Vitale, PhD, Esteban Braggio, PhD, Arianna Di Napoli, Amy Chadburn, MD, John N. Allan, MD, Richard R. Furman, MD, Langdon L. Miller, Brian J Lanutti, PhD, Silvia Deaglio, MD PhD

Blood (2019) 134 (Supplement_1): 2856.

https://doi.org/10.1182/blood-2019-126827

Published: 2019

Journal Articles

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

Cecilia Bonolo De Campos, PhD, Caleb K Stein, PhD, Nathalie Meurice, PhD, Laura Ann Bruins, BS, Joachim L Petit, PhD, Alysia N Polito, BS, Gregory J Ahmann, BS, Shulan Tian, MS, PhD, P. Leif Bergsagel, MD, Esteban Braggio, PhD, A. Keith Stewart, MB, ChB

Blood (2019) 134 (Supplement_1): 574.

https://doi.org/10.1182/blood-2019-130977

Published: 2019

Journal Articles

A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood (2019) 134 (Supplement_1): 4306.

https://doi.org/10.1182/blood-2019-123824

Published: 2019

Journal Articles

The Contribution of Proteasome Subunits to Myeloma Cell Viability and Proteasome Inhibitor Sensitivity

Chang-Xin Shi, PhD, Yuan Xiao Zhu, PhD, Laura Ann Bruins, BS, Cecilia Bonolo De Campos, PhD, William Stewart, Esteban Braggio, PhD, A Keith Stewart, M.B. Ch.B.

Blood (2019) 134 (Supplement_1): 4337.

https://doi.org/10.1182/blood-2019-127149

Published: 2019

Journal Articles

Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide

Sinto Chirackal, PhD, Esteban Braggio, PhD, Rahman Atiqur, PhD, Gregory J Ahmann, BS, Yuan Xiao Zhu, PhD, A. Keith Stewart, MB, ChB, Marta Chesi, PhD, P. Leif Bergsagel, MD, Rafael Fonseca, MD

Blood (2019) 134 (Supplement_1): 4410.

https://doi.org/10.1182/blood-2019-124967

Published: 2019

Journal Articles

Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance

Jonas Paludo, MD, Surendra Dasari, PhD, Kerstin Wenzl, PhD, Shahrzad Jalali, PhD, Jordan Krull, Michelle Manske, MS, BS, Esteban Braggio, PhD, Prashant Kapoor, MD, Aneel Paulus, MD, Sikander Ailawadhi, MD, Craig B. Reeder, MD, Allison C. Rosenthal, DO, Robert A. Kyle, MD, Morie A Gertz, MD, Anne J Novak, PhD, Stephen M Ansell, MD PhD

Blood (2019) 134 (Supplement_1): 2774.

https://doi.org/10.1182/blood-2019-128912

Published: 2019

Journal Articles

Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL)

Nicholas J Boddicker, PhD, Daniel R O'Brien, Esteban Braggio, PhD, Sara J. Achenbach, Kari G. Chaffee, MS, Aaron D. Norman, Celine M. Vachon, PhD, Brian Kabat, B.S., Timothy G. Call, MD, Sameer A. Parikh, MD, Jose F. Leis, MD PhD, Wei Ding, MD PhD, Eli Muchtar, MD, James R. Cerhan, MD PhD, Tait D. Shanafelt, MD, Neil E. Kay, MD, Neil E Caporaso, Susan L. Slager, PhD

Blood (2018) 132 (Supplement 1): 3116.

https://doi.org/10.1182/blood-2018-99-117044

Published: 2018

NARROW

Identification of a Novel Role for PD-1 Signaling in Promotion Tumor Proliferation in B-Cell Lymphoma

Genomic Profiling Reveals Molecular Heterogeneity in Patients with Richter's Syndrome (RS) and Progressive Chronic Lymphocytic Leukemia (CLL)

Long-Term Efficacy of First-Line Ibrutinib Treatment for Chronic Lymphocytic Leukemia (CLL) With 4 Years of Follow-Up in Patients With TP53 Aberrations (del(17p) or TP53 Mutation): A Pooled Analysis From 4 Clinical Trials

Polygenic Risk Score and Risk of Chronic Lymphocytic Leukemia, Monoclonal B-Cell Lymphocytosis (MBL), and MBL Subtypes

Clinical Characteristics and Outcomes of Newly Diagnosed Patients with Chronic Lymphocytic Leukemia Who Are 80 Years of Age or Older

Impact of Deletion6q23 Identified By FISH in Patients with Chronic Lymphocytic Leukemia

Measles, Mumps & Rubella Titers Post Autologous Stem Cell Transplant in Multiple Myeloma Patients Induced with Modern Therapy

Distinct Gene Expression Signatures in Patients with Richter's Syndrome and Chronic Lymphocytic Leukemia with Prior Exposure to Ibrutinib

Targeting Aberrant Chromatin in Chronic Lymphocytic Leukemia

Tumor Mutational Load and Germline Polygenic Risk Score Predicts Time-to-First Treatment in Chronic Lymphocytic Leukemia (CLL) and High-Count Monoclonal B Cell Lymphocytosis (MBL)

Ibrutinib and Rituximab Provides Superior Clinical Outcome Compared to FCR in Younger Patients with Chronic Lymphocytic Leukemia (CLL): Extended Follow-up from the E1912 Trial

Developmental DNA Methylation Subtype Predicts Progression to Treatment and Survival in High-Count Monoclonal B Lymphocytosis

BTK and/or PLCG2 Mutations in Patients with Chronic Lymphocytic Leukemia (CLL) Treated with Ibrutinib: Characteristics and Outcomes at the Time of Progression

Vls-101 Is a Novel Therapeutic Antibody-Drug Conjugate (ADC) Targeting Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) in Richter's Syndrome (RS)

Integrative Analysis of FISH, Transcriptomics and Mutational Status Predicts Responsiveness to Novel Agents in Multiple Myeloma

A Randomized Phase 2 Study Comparing Acalabrutinib with or without Obinutuzumab in the Treatment of Early Stage High Risk Patients with Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

The Contribution of Proteasome Subunits to Myeloma Cell Viability and Proteasome Inhibitor Sensitivity

Myeloma Cells Addicted to Glutamine for Biomass Production Are Sensitive to Lenalidomide

Long Non-Coding RNA Expression in Waldenstrom Macroglobulinemia and IgM Monoclonal Gammopathy of Undetermined Significance

Clonal Hematopoiesis of Indeterminate Potential (CHIP) and Chronic Lymphocytic Leukemia (CLL) Driver Genes: Risk of CLL and Monoclonal B-Cell Lymphocytosis (MBL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only